CRA recently updated its 2011 review of health technology assessment (HTA) policies, and widened the assessment to cover 16 countries including emerging markets that have recently implemented HTA. Click the link below for a summary of key findings, with a link to the full report.
CRA's RADAR Insights: Impact of US pricing strategies on orphan drug pricing in Germany - Part 3
In Part 3 of this series, RADAR data on orphan-drug pricing in Germany revealed a significant increase in manufacturer-set list prices for new orphan drugs...